Reflections from ASRS - Summary - MDSpire

Reflections from ASRS

Upfront: Monthly reflection by Editor in Chief Diana V. Do, MD.

  • By

  • Diana V. Do, MD

  • September 1, 2025

  • 3 min

Share

Objective:

To summarize key insights and developments presented at the ASRS annual meeting, focusing on ocular oncology, pediatric retina, and uveitis treatments, while also reflecting on the networking and educational opportunities available.

Key Findings:
  • Timely diagnosis is crucial for preventing vision loss in ocular tumors, as emphasized by multiple speakers.
  • AI can enhance the diagnosis and monitoring of retinopathy of prematurity, potentially changing standard practices.
  • IL-6 inhibitors are a promising area of research for treating noninfectious uveitis, with ongoing studies discussed.
  • The PDS for ranibizumab presents both efficacy and safety challenges, as highlighted in the controversies session.
Interpretation:

The ASRS meeting highlighted significant advancements in retinal care, emphasizing the integration of new technologies and treatment strategies, and their implications for clinical practice.

Limitations:
  • Not all retinal topics could be covered due to time constraints at the conference, including emerging therapies and techniques.
  • The adoption of new technologies like the PDS may face practical challenges, including safety concerns and clinician training.
Conclusion:

The ASRS meeting reinforced the importance of continuous education and collaboration within the retina community to enhance patient care.

Original Source(s)

Reflections from ASRS

  • by Diana V. Do, MD

  • September 1, 2025

Related Content

Expanding the Role of Suprachoroidal Injections

Clinical data support this targeted route for small molecules, gene therapy, and oncologic agents, with a good safety profile and potential to reduce treatment burden.

Imaging Leukocyte Dynamics in Retinal Disease

The movement of immune cells through the retinal vasculature has long been inferred from laboratory models. Now, advances in imaging are allowing clinicians to observe these processes directly. At the 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Denver, Richard B. Rosen, MD, ScD(hon), FACS, FASRS, FARVO, described early clinical work using adaptive optics scanning laser ophthalmoscopy (AOSLO) to visualize leukocyte trafficking in vivo.

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized